While melanocytes have strong mechanisms for repair, those in individuals with certain risk factors may carry impaired repair responses. Studies have begun to examine melanocytes in patients at risk for developing melanoma with the hope of developing strategies for preventing deadly tumors.
A recent study provides more evidence that patients with psoriasis–even mild cases–face a higher risk of major depression, a finding that could lead dermatologists to alert patients with the condition and even screen them for mental health issues.
I believe that the only way to increase diversity in medicine and particularly dermatology is to begin this process early in school age children. Here's what I suggest.
Should dermatologists be required to disclose matters of personal health, especially if matters related to physician health may increase the risk of harm to a patient?
This month, we examine how to recognize Zika virus, a new therapeutic option for AD, and the concept of field cancerization in treating actinic keratosis.
A wearable skin patch (Viaskin, DBV Technologies) may help treat peanut allergy, specifically in children and young adults, according to one-year results of an ongoing trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and conducted by the NIAID-funded Consortium of Food Allergy Research(CoFAR).
Neuroinflammation has recently been recognized as one of the possible factors leading to the development of rosacea. As such, future therapies targeting this pathway could prove effective in rosacea treatment.
Cumulative dosing of isotretinoin has followed a reference range of 120 to 150 mg/kg, but there is an absence of strong evidence supporting this recommendation, pointing to the need for clinicians to treat their patients to achieve clearance of acne rather than adhere to this range.
Researchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.
Despite increased insight on skin cancer risk factors, the incidence continues to rise worldwide. This review article summarizes new treatment options available, which help to redefine and expand the diagnosis of advanced BCC and allow dermatologists to offer more effective therapy to a broader population.
Ten tips for developing a social media marketing policy that will help you avoid pitfalls and stay relevant while giving your practice a glowing social presence and reputation.
The third in our series on out-of-control drug costs highlights strategies that should work to stabilize the costs of medications, so that they’re more affordable for patients.
Filling more challenging areas such as the temples, frontalis, tear trough, jawline and chin can help dermatologists and other core aesthetic specialists stand out among providers of injectable treatments, an expert says.
Experts discuss diagnosis and management of pediatric melanoma, including the latest developments in genetic tools and indications for sentinel lymph node biopsy.
My interest in etymology, (not to be confused with entomology) has grown along with the importance of precise and efficient EMR documentation. Along the way, I learned some great words and acronyms and made up a few of my own.
An expert goes over the pros and cons of some of the available OTC acne products.
An expert discusses which types of products tend to be more comdedogenic and acnegenic.
An expert discusses available types of facial foundations and their effect on the skin in regards to acne.
Agents that can attack melasma on multiple fronts include retinoids, glucosamine, hydroquinone, topical steroids, phytosterol, glycyrrhetinic acid, niacinamide, soybean extracts, retinoids, salicylic acid and liquirtin, an expert says.
A new study using crowdsourcing harnesses the power of social media chatter to better understand unmet needs in eczema research.
Tickborne diseases are a significant health problem in the United States with over 40,000 confirmed or probable cases reported as recently as 2014. Almost 80% of these cases consist of Lyme disease, but other diseases, including viral infections, are present and have been increasing in number over the past 20 years. Experts in tickborne diseases share updates about what’s new and what’s changing in the detection and transmission of these diseases.
A report published by U.S. based market research company Grand View Research suggests the global skincare products market will reach $196.67 billion by 2024, up from an estimated $129.21 billion in 2015.
Skincare product formulating is a natural for dermatologists, but there are several important considerations before starting what can be an expensive, time-consuming process.
Managing referrals successfully requires being honest with patients and equitable with peers, experts say.
There are important differences in and misconceptions about the prevalence, clinical presentation and treatment of skin of color versus Caucasian psoriasis patients. Dermatologist Andrew F. Alexis, M.D., M.P.H., share his insight about what dermatologists need to know when treating psoriasis skin of color patients.
Based on available evidence, dermatologists should at least discuss biologic drugs with patients who have moderate-to-severe psoriasis and cardiovascular comorbidities. Clearing the skin may improve cardiovascular disease, says an expert.
Many children with eczema suffer from bullying because of the skin condition. A new survey reflects what children and caregivers are experiencing, beyond the itch.
Microbial colonization in the development of inflammatory conditions and immune-mediated conditions is a hot research topic, and new dermatologic therapies can potentially result from greater understanding of the role of microbial communities on the skin and in the gut.
This month we offer new insights and data to aid diagnosis and treatment of difficult conditions, as well as practical approaches to optimize outcomes.
The FDA approved the biosimilars Erelzi for plaque psoriasis and Enbrel for psoriatic arthritis.
